Quantitative radiopharmaceutical imaging
Identification of functional abnormalities in individual patients is based on the evidence from normal databases specific to each function and each radiopharmaceutical. The group is developing and implementing into the clinics new algorithms for the quantification of the tissue/organ biomarker (radiopharmaceutical) uptake during the different stages of disease evolution and after therapy to assess response. This has been done through computer automated diagnosis (CAD) systems that employ lesion anatomical identification, classification and intensity evaluation for automatic mapping of disease extension and severity.
